Statin Use and the Risk of Type 2 Diabetes Mellitus in Children and Adolescents

Academic Pediatrics

Volumn 17, Issue 5, 2017, Pages 515-522

  Joyce, Nina R ^a,b   Zachariah, Justin P ^c   Eaton, Charles B ^a   Trivedi, Amal N ^a   Wellenius, Gregory A ^a  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

diabetes; dyslipidemia; familial hypercholesterolemia; pharmacoepidemiology; statin

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; CENTRAL STIMULANT AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; NEUROLEPTIC AGENT; VITAMIN D;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED PRACTICE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROPENSITY SCORE; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; COMPLICATION; RISK ASSESSMENT;

ADOLESCENT; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROPENSITY SCORE; RISK ASSESSMENT;

EID: 85017138493     PISSN: 18762859     EISSN: 18762867     Source Type: Journal    
DOI: 10.1016/j.acap.2017.02.006     Document Type: Article

References (34)

1. Joyce, N., Wellenius, G.A., Dore, D.D., et al. Patterns of lipid lowering therapy among children ages 8–20 years. J Pediatr 167 (2015), 113–119.e1.
2. Daniels, S.R., Greer, F.R., Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 122 (2008), 198–208.
3. de Ferranti, S., Ludwig, D.S., Storm over statins—the controversy surrounding pharmacologic treatment of children. N Engl J Med 359 (2008), 1309–1312.
4. Staffa, J.A., Chang, J., Green, L., Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002), 539–540.
5. Newman, C.B., Palmer, G., Silbershatz, H., et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92 (2003), 670–676.
6. Thompson, P.D., Clarkson, P., Karas, R.H., Statin-associated myopathy. JAMA 289 (2003), 1681–1690.
7. Avis, H.J., Vissers, M.N., Stein, E.A., et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 27 (2007), 1803–1810.
8. Ridker, P.M., Pradhan, A., MacFadyen, J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380 (2012), 565–571.
9. Sattar, N., Preiss, D., Murray, H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010), 735–742.
10. Culver, A.L., Ockene, I.S., Balasubramanian, R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 172 (2012), 144–152.
11. Barylski, M., Nikolic, D., Banach, M., et al. Statins and new-onset diabetes. Curr Pharm Des 20 (2014), 3657–3664.
12. Danaei, G., Garcia Rodriguez, L.A., Fernandez Cantero, O., et al. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care 36 (2013), 1236–1240.
13. Dormuth, C.R., Filion, K.B., Paterson, J.M., et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ, 348, 2014, g3244.
14. Lotta, L.A., Sharp, S.J., Burgess, S., et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 316 (2016), 1383–1391.
15. Swerdlow, D.I., Preiss, D., Kuchenbaecker, K.B., et al. HMG–coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385 (2015), 351–361.
16. US Food and Drug Administration. FDA announces safety changes in labeling for some cholesterol-lowering drugs. News release, February 28, 2012. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. Accessed February 25, 2017.
17. Ma, Y., Culver, A., Rossouw, J., et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?. Ther Adv Cardiovasc Dis 7 (2013), 41–44.
18. Austin, M.A., Hutter, C.M., Zimmern, R.L., et al. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 160 (2004), 421–429.
19. Yuan, G., Wang, J., Hegele, R.A., Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 174 (2006), 1124–1129.
20. Besseling, J., Kastelein, J.J., Defesche, J.C., et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 313 (2015), 1029–1036.
21. Fuentes, F., Alcala-Diaz, J.F., Watts, G.F., et al. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: the SAFEHEART study. Int J Cardiol 201 (2015), 79–84.
22. Ray, W.A., Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158 (2003), 915–920.
23. Andrade, S.E., Kahler, K.H., Frech, F., et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15 (2006), 565–574.
24. Robinson, J.G., Statins and diabetes risk: how real is it and what are the mechanisms?. Curr Opin Lipidol 26 (2015), 228–235.
25. Kohli, P., Waters, D.D., Nemr, R., et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol 65 (2015), 402–404.
26. Austin, P.C., A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27 (2008), 2037–2049.
27. Ho, D., Kosuke, I., King, G., et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Analysis 15 (2007), 199–236.
28. Dart, A.B., Martens, P.J., Sellers, E.A., et al. Validation of a pediatric diabetes case definition using administrative health data in Manitoba, Canada. Diabetes Care 34 (2011), 898–903.
29. Bobo, W.V., Cooper, W.O., Stein, C.M., et al. Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. BMC Med Res Methodol, 12, 2012, 128.
30. Preiss, D., Seshasai, S.R., Welsh, P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305 (2011), 2556–2564.
31. Dixon, D.B., Kornblum, A.P., Steffen, L.M., et al. Implementation of lipid screening guidelines in children by primary pediatric providers. J Pediatr 164 (2014), 572–576.
32. Pettitt, D.J., Talton, J., Dabelea, D., et al. Prevalence of diabetes in US youth in 2009: the SEARCH for Diabetes in Youth study. Diabetes Care 37 (2014), 402–408.
33. Belamarich, P.F., Counterpoint: the evidence does not support universal screening and treatment in children. J Clin Lipidol 9 (2015), S101–S106.
34. Psaty, B.M., Rivara, F.P., Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA 307 (2012), 257–258.